In today's world, Amperozide has become a topic of great relevance and interest to a wide variety of people. Whether we are talking about Amperozide in the historical, social, technological or scientific context, its impact and significance are undeniable. In recent decades, interest in Amperozide has grown exponentially, leading to greater analysis and discussion of its implications and consequences. From its origins to its future, Amperozide is a topic that sparks passionate debates and conflicting opinions, which makes its study essential to understanding the world around us. In this article, we will explore different perspectives and approaches on Amperozide, with the aim of providing a broad and enriching view on this important topic.
Amperozide is an atypical antipsychotic of the diphenylbutylpiperazine class which acts as an antagonist at the 5-HT2Areceptor. It does not block dopamine receptors as with most antipsychotic drugs, but does inhibit dopamine release, and alters the firing pattern of dopaminergic neurons. It was investigated for the treatment of schizophrenia in humans, but never adopted clinically. Its main use is instead in veterinary medicine, primarily in intensively farmed pigs, for decreasing aggression and stress and thereby increasing feeding and productivity.
^Meltzer HY, Zhang Y, Stockmeier CA (May 1992). "Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action". European Journal of Pharmacology. 216 (1): 67–71. doi:10.1016/0014-2999(92)90210-u. PMID1388121.
^Eriksson E (1990). "Amperozide, a putative anti-psychotic drug: uptake inhibition and release of dopamine in vitro in the rat brain". Life Sciences. 47 (23): 2111–7. doi:10.1016/0024-3205(90)90310-n. PMID1979998.
^Yamamoto BK, Meltzer HY (October 1992). "The effect of the atypical antipsychotic drug, amperozide, on carrier-mediated striatal dopamine release measured in vivo". The Journal of Pharmacology and Experimental Therapeutics. 263 (1): 180–5. PMID1403783.
^Grenhoff J, Tung CS, Ugedo L, Svensson TH (1990). "Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo". Pharmacology & Toxicology. 66 (Suppl 1): 29–33. doi:10.1111/j.1600-0773.1990.tb01603.x. PMID2304893.
^Axelsson R, Nilsson A, Christensson E, Björk A (1991). "Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist". Psychopharmacology. 104 (3): 287–92. doi:10.1007/bf02246025. PMID1924636. S2CID2507927.
^Kyriakis SC, Martinsson K, Olsson NG, Bjork A (1990). "Thin sow syndrome (TSS): the effect of amperozide". The British Veterinary Journal. 146 (5): 463–7. doi:10.1016/0007-1935(90)90036-3. PMID2224491.
^Kyriakis SC, Olsson NG, Martinsson K, Björk AK (September 1991). "Observations on the action of amperozide: are there social influences on sow-litter productivity?". Research in Veterinary Science. 51 (2): 169–73. doi:10.1016/0034-5288(91)90008-C. PMID1788479.
^Papp I, Waller C, Biro O (October 1996). "". Berliner und Munchener Tierarztliche Wochenschrift. 109 (10): 385–7. PMID8999770.